Axovant Gene Therapies Ltd (NASDAQ:AXGT) – Analysts at Svb Leerink dropped their Q4 2020 earnings estimates for Axovant Gene Therapies in a research report issued on Thursday, December 5th, according to Zacks Investment Research. Svb Leerink analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.62) for the quarter, down from their previous estimate of ($0.61). Svb Leerink also issued estimates for Axovant Gene Therapies’ Q2 2021 earnings at ($0.70) EPS, FY2021 earnings at ($2.68) EPS, FY2022 earnings at ($2.54) EPS and FY2023 earnings at ($2.76) EPS.
Several other brokerages have also issued reports on AXGT. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a “hold” rating to a “strong-buy” rating and set a $6.00 target price for the company in a research report on Wednesday, November 13th. Chardan Capital lifted their price target on Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Axovant Gene Therapies has a consensus rating of “Buy” and an average price target of $24.72.
Shares of NASDAQ:AXGT opened at $5.21 on Monday. Axovant Gene Therapies has a one year low of $3.81 and a one year high of $19.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market capitalization of $118.75 million, a price-to-earnings ratio of -0.65 and a beta of 1.20. The company’s fifty day moving average price is $5.35 and its 200-day moving average price is $6.19.
Axovant Gene Therapies (NASDAQ:AXGT) last announced its earnings results on Friday, November 8th. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.54.
Several institutional investors and hedge funds have recently made changes to their positions in AXGT. Tower Research Capital LLC TRC boosted its stake in shares of Axovant Gene Therapies by 955.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock valued at $27,000 after purchasing an additional 3,821 shares in the last quarter. Barclays PLC bought a new stake in Axovant Gene Therapies in the third quarter worth $65,000. Jane Street Group LLC lifted its stake in Axovant Gene Therapies by 28.8% in the second quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock worth $289,000 after purchasing an additional 10,375 shares during the last quarter. Finally, BlackRock Inc. purchased a new stake in Axovant Gene Therapies during the second quarter valued at about $1,482,000. Hedge funds and other institutional investors own 14.80% of the company’s stock.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson’s disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
